ArticleJournal of personalized medicine2021
Risk Factors of 30-Day All-Cause Mortality in Patients with Carbapenem-Resistant
Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- Eravacycline in Critically Ill Patients with Multidrug-Resistant Gram-Negative Infections: A Real-World Cohort Study.Journal of clinical medicine · 2026Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Clinical Epidemiological Analysis of the Genotypic Spectrum and Mortality Risk in Carbapenem-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Multisite Infections Caused by Carbapenem-Resistant Klebsiella Pneumoniae: Unveiling the Clinical Characteristics and Risk Factors.Antibiotics (Basel, Switzerland) · 2025Article
- Predictive Value of Infection Related Critical Illness Scores on the Risk of Death in Infected Patients: A Systematic Review and Meta-Analysis.Iranian journal of public health · 2025Review
- Rapid Identification of Carbapenem-ResistantInfection and drug resistance · 2025Article
- Article
- Association between clinical-biological characteristics of Klebsiella pneumoniae and 28-day mortality in patients with bloodstream infection.BMC microbiology · 2024Article
- Retrospective analysis of molecular characteristics, risk factors, and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.BMC microbiology · 2024Observational
- GC-IMS facilitates identification of carbapenem-resistant Klebsiella pneumoniae in simulated blood cultures.AMB Express · 2024Article
- Developing and validating a machine learning model to predict multidrug-resistantFrontiers in immunology · 2024Article
- Clinical and epidemiological characteristics of multi-drug resistantJournal of medicine and life · 2024Article
- Clinical and Microbiological Risk Factors for 30-Day Mortality of Bloodstream Infections Caused by OXA-48-ProducingPathogens (Basel, Switzerland) · 2023Article
- Evaluation of Potential Factors Influencing the Dissemination of Multidrug-ResistantTropical medicine and infectious disease · 2023Review
- Personalized and Precision Medicine 2022.Journal of personalized medicine · 2023Article
- Clinical Characteristics and Prognosis of Bloodstream Infection with Carbapenem-ResistantInfection and drug resistance · 2023Article
- Comparison of bloodstream and non-bloodstream infections caused by carbapenem-resistantFrontiers in medicine · 2023Article
- Characteristics of bloodstream infection and initial antibiotic use in critically ill burn patients and their impact on patient prognosis.Scientific reports · 2022Article
- Molecular Epidemiology, Clinical Characteristics and Risk Factors for Bloodstream Infection of Multidrug-ResistantInfection and drug resistance · 2022Article
- Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review.Infection and drug resistance · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An optimal antimicrobial regimen for the treatment of patients with carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.